Sign in
TerminatedPhase 1

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Key facts

Who runs it
TG Therapeutics, Inc.
Where
Chattanooga, Fayetteville, Hackensack, Houston, and Nashville, United StatesSee the 5 sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
21 people enrolled
Started
28 Apr 2021
Ended
12 Jun 2024
Type of study
Interventional, 3 groups
Treatments tested
  • TG-1801
  • Ublituximab
Record updated
31 July 2024
Why it stopped
Strategic/Business Decision

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • B-cell non-Hodgkin lymphoma (NHL) including Richter's Transformation (RT) and transformed follicular lymphoma (FL), that warrants systemic therapy
  • Chronic Lymphocytic Leukemia (CLL), that warrants systemic therapy as defined by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) (Hallek 2018)
  • Treatment Status:; NHL subjects: relapsed to or refractory after at least two prior standard systemic therapies (excluding antibiotics); RT subjects: relapsed or refractory after at least two prior lines of therapy for CLL/ Small lymphocytic lymphoma (SLL) or RT; CLL subjects: relapsed to or refractory after at least two prior standard therapies
  • Measurable disease defined as:; NHL (including SLL): at least 1 measurable disease lesion > 1.5 centimeters (cm); CLL: at least 1 measurable disease lesion

Who cannot take part

  • Prior therapy with any agent blocking the CD47/SIRPα pathway or any previous CD19 targeting therapy,
  • Subjects receiving cancer therapy (i.e. chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization) or any investigational drug within 21 days of Cycle 1 Day 1
  • Prior autologous stem cell transplant (SCT) within 6 months

Where in United States

  • Chattanooga, TennesseeHospital not named in the registry
  • Fayetteville, ArkansasHospital not named in the registry
  • Hackensack, New JerseyHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Nashville, TennesseeHospital not named in the registry

About the trial

What the trial wants to find out

The primary objective of this study is to determine the recommended phase 2 dose (RP2D) and characterize the safety profile of TG-1801. As per protocol v3.0, ublituximab will be discontinued.

The 3 groups in the trial

  • Cohort A: TG-1801Treatment being tested

    TG-1801 Single Agent As per protocol v3.0, Cohort A is no longer enrolling.

    Treatment: TG-1801

  • Cohort B: TG-1801Treatment being tested

    TG-1801 Single Agent, escalating doses

    Treatment: TG-1801

  • Cohort C: TG-1801 + UblituximabTreatment being tested

    TG-1801 in combination with ublituximab As per protocol v3.0, ublituximab will be discontinued and the Cohort C is no longer enrolling.

    Treatment: TG-1801 and Ublituximab

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Record updated
31 July 2024